All News

A look at Medicare Part D drug plans and drug pricing and the plans of the current administration.

Objective considerations when gauging investment.

Click the title above to open the Pharmaceutical December 2018 issue in an interactive PDF format.

With a reputation as a reliable, if somewhat unspectacular, marketplace, Malaysia has long appealed to life science investors lured in by the prospect of generating consistent returns.

A Q&A with Mylan’s President, Rajiv Malik about what progresses our society has made to fight HIV, what challenges companies face in tackling medicine delivery to developing countries, and bringing those innovations back to our own country.

One year after the Merck cyber attack pharma takes stock of what the industry has learned and what to do moving forward.

Click the title above to open the Pharmaceutical November 2018 issue in an interactive PDF format.

Despite a recent whirlwind of changes and policy reshuffling in Algeria’s life science space, the nation’s marketplace remains a high priority for multinationals investing in the Middle East and North Africa (MENA).

Pharm Exec’s 11th annual list of rising leaders highlights 10 pharma managers who are poised to help chart the industry’s path forward.

As this year's installment of our Emerging Pharma Leaders shows, the current roadmap for a career in biopharma requires its own "Waze"-like navigation.